EUVIMEDEUVIMED entdecken
Open Access

Utility of Serum Matrix Metalloproteinase-7 as a Biomarker in Cholestatic Infants with Congenital Heart Disease

Sindhu Pandurangi, Michael E Kim, Nicolas Noriega, Bradley Conant, JangDong Seo, Reena Mourya, Pranavkumar Shivakumar, Anna L Peters, Andrew Misfeldt, Meghan Chlebowski

Pediatric Cardiology · 2025

DOI: 10.1007/s00246-024-03696-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Cardiology, 2025. Verfasst von Sindhu Pandurangi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Children's Medical Center of Dallas and Division of Pediatric Gastroenterology, Hepatology, and Nutrition of the Department of Pediatrics, University…. Hauptthemen laut MEDLINE: Matrix Metalloproteinase 7, Heart Defects, Congenital, Biliary Atresia, Cholestasis. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Matrix metalloproteinase 7 (MMP-7) is a novel biomarker for diagnosis of biliary atresia (BA), the most common cholestatic liver disease in infancy. There is a pressing need to determine the utility of MMP-7 levels in infants with congenital heart disease (CHD) to avoid unnecessary invasive diagnostic procedures in this high-risk population. We investigated the utility of MMP-7 in discriminating BA from non-BA cholestasis in infants with CHD and whether MMP-7 elevation was present in infants requiring treatment for clinically significant PH. METHODS: This is a single-center cross-sectional study including infants < 180 days of age with cholestasis and serum MMP-7 levels collected from 2019 to 2023. Demographic data and descriptive statistics were summarized with medians with interquartile ranges and frequencies with percentages. Median MMP-7 levels were assessed via Wilcoxon rank-sum test. RESULTS: A total of 149 patients were included. Patients with CHD had significantly elevated MMP-7 levels relative to the non-CHD cohort (50 vs. 34 ng/mL, p = 0.009). Sub-analysis comparing infants with and without PH revealed significantly elevated median MMP-7 levels in those with clinically significant PH (125 vs. 39 ng/mL, p = 0.010). CHD patients with PH had greater median MMP-7 compared to CHD patients without PH (154 vs 43 ng/mL, p = 0.028). CONCLUSION: Serum MMP-7 levels in infants with congenital heart disease with cholestasis (CHD-C) were significantly elevated compared to those with cholestasis alone. MMP-7 may help identify non-BA cholestatic infants who have concurrent clinically significant pulmonary hypertension. Larger, prospective studies are needed to validate this finding and establish CHD-specific MMP-7 cut-offs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Matrix Metalloproteinase 7Heart Defects, CongenitalBiliary AtresiaCholestasisHumansBiomarkersMaleFemaleInfantCross-Sectional StudiesInfant, Newborn

Stichwörter der Autor:innen

Biliary atresiaBiomarkerCholestasisCongenital heart diseaseMMP-7Pulmonary hypertension

Substanzen

Matrix Metalloproteinase 7BiomarkersMMP7 protein, human

Autor:innen und Institutionen

  • Children's Medical Center of Dallas and Division of Pediatric Gastroenterology, Hepatology, and Nutrition of the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Department of Critical Care Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Division of Pediatric Cardiology, Heart Institute, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Pandurangi, S., Kim, M. E., Noriega, N., Conant, B., Seo, J., Mourya, R., Shivakumar, P., Peters, A. L., Misfeldt, A., & Chlebowski, M. (2025). Utility of Serum Matrix Metalloproteinase-7 as a Biomarker in Cholestatic Infants with Congenital Heart Disease. Pediatric Cardiology. https://doi.org/10.1007/s00246-024-03696-2

Vancouver

Pandurangi S, Kim ME, Noriega N, Conant B, Seo J, Mourya R, et al. Utility of Serum Matrix Metalloproteinase-7 as a Biomarker in Cholestatic Infants with Congenital Heart Disease. Pediatric Cardiology. 2025. doi:10.1007/s00246-024-03696-2

BibTeX
@article{Pandurangi2025,
  author = {Pandurangi, Sindhu and Kim, Michael E and Noriega, Nicolas and Conant, Bradley and Seo, JangDong and Mourya, Reena and Shivakumar, Pranavkumar and Peters, Anna L and Misfeldt, Andrew and Chlebowski, Meghan},
  title = {Utility of Serum Matrix Metalloproteinase-7 as a Biomarker in Cholestatic Infants with Congenital Heart Disease},
  journal = {Pediatric Cardiology},
  year = {2025},
  doi = {10.1007/s00246-024-03696-2}
}
Kostenlos starten →